Safety of dietary supplements including n-3 PUFA (Imark S®) for the maintenance of remission in patients with Crohn's disease: A pilot study.
Phase 1
- Conditions
- Crohn's disease
- Registration Number
- JPRN-UMIN000012585
- Lead Sponsor
- Osaka University Graduate School Department of Complementary and Alternative Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with the following diseases. (cirrhosis, chronic renal failure, diabetes with insulin therapy and so on) 2) Patients with steroid treatment 3) Patients with anti-TNF agents treatment 4) Patients with food allergy 5) Patients less than 20 years old. 6) Patients with xerosis cutis and impossible to measure body composition 7) Patients judged to be inappropriate for this study from the doctor in charge.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method